BNP AND NT-PRO BNP AS INDEPENDENT DIAGNOSTIC BIOMARKERS FOR CARDIOVASCULAR DISEASE IN TYPE 2 DIABETES MELLITUS

Authors

  • Balaji Vijayam Department of Diabetology, Dr. V Balaji Diabetes Care and Research Institute, Chennai, Tamil Nadu, India.
  • Taarika Balaji Department of Medicine, Saveetha Institute of Technical and Medical Sciences, Chennai, Tamil Nadu, India.
  • Madhuri S Balaji Department of Medical Research, Dr. V Balaji Diabetes Care and Research Institute, Chennai, Tamil Nadu, India.
  • Seshiah Veerasamy Department of Diabetology, Dr. V Balaji Diabetes Care and Research Institute, Chennai, Tamil Nadu, India.
  • Vinoth Kumar Ganesan Department of Medical Research, Dr. V Balaji Diabetes Care and Research Institute, Chennai, Tamil Nadu, India.

DOI:

https://doi.org/10.22159/ijms.2022.v10i5.45992

Keywords:

T2DM, CVD, Biomarker, BNP, NT-proBNP

Abstract

The risk of developing heart failure (HF) with a reduced and preserved ejection fraction is known to increase with pre-diabetes and diabetic mellitus (DM). Natriuretic peptides (NPs) have been shown to be an important tool for assessing the risk of cardiovascular diseases (CVD) in people with pre-diabetes and Type 2 diabetes (T2DM), regardless of HF characteristics. Elevated levels of NPs were associated with an increased risk of readmission for HF, all-cause mortality, CVD mortality, HF progression, and readmission due to HF, according to earlier clinical investigations. In pre-diabetes and T2DM populations, the discriminative power of NPs for CVD death and HF-related clinical events has not been established beyond conventional CVD risk variables. The purpose of the review is to gather details regarding the predictive value of circulating NPs based on pre-diabetes and established T2DM presentation. Researchers have found that HFrEF or HFpEF in T2DM patients may necessitate a change in NP cutoff values to diagnose primary HF and identify HF-related risks. The relationship between clinical outcomes and the dynamic of circulating levels of NPs in diabetics treated with glucagon-like peptide-1 agonists and sodium-glucose cotransporter-2 inhibitors has to be clarified in big clinical trials in the future.

References

Weber M, Mitrovic V, Hamm C. B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide–Diagnostic role in stable coronary artery disease. Experimental & Clinical Cardiology. 2006;11(2):99.

Tao Z, Shi A, Zhao J. Epidemiological perspectives of diabetes. Cell Biochem Biophys 2015; 73:181‑5.

Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR,Cheng S, et al. Heart Disease and Stroke Statistics‑2018 Update: A Report From the American Heart Association. Circulation 2018;137: e67‑e492.

Cavender MA, Steg PG, Smith SC Jr., Eagle K, Ohman EM, Goto S, et al. Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: Outcomes at 4 years from the reduction of atherothrombosis for continued health (REACH) Registry. Circulation 2015; 132:923‑31.

Selvin E, Parrinello CM, Sacks DB, Coresh J. Trends in prevalence and control of diabetes in the United States, 1988‑1994 and 1999‑2010. Ann Intern Med 2014; 160:517‑25.

Bae JC, Cho NH, Suh S, Kim JH, Hur KY, Jin SM, et al. Cardiovascular disease incidence, mortality and case fatality related to diabetes and metabolic syndrome: A community‑based prospective study (Ansung‑Ansan cohort 2001‑12). J Diabetes 2015; 7:791‑9.

Strain WD, Paldánius PM. Diabetes, cardiovascular disease and the microcirculation. Cardiovasc Diabetol 2018; 17:57.

Alvarez CA, Lingvay I, Vuylsteke V, Koffarnus RL, McGuire DK. Cardiovascular Risk in diabetes mellitus: Complication of the disease or of antihyperglycemic medications. Clin Pharmacol Ther 2015; 98:145‑61.

Yang YS, Yang BR, Kim MS, Hwang Y, Choi SH. Low‑density lipoprotein cholesterol goal attainment rates in high‑risk patients with cardiovascular diseases and diabetes mellitus in Korea: A retrospective cohort study. Lipids Health Dis 2020; 19:5.

Balakumar P, Maung‑U K, Jagadeesh G. Prevalence and prevention of cardiovascular disease and diabetes mellitus. Pharmacol Res 2016; 113:600‑9.

Berezin AE. Prognostication of clinical outcomes in diabetes mellitus: Emerging role of cardiac biomarkers. Diabetes Metab Syndr 2019; 13:995‑1003.

Berezin AE. Cardiac biomarkers in diabetes mellitus: New dawn for risk stratification? Diabetes Metab Syndr 2017;11 Suppl 1: S201‑8.

Published

04-09-2022

How to Cite

Vijayam, B., Balaji, T., Balaji, M. S., Veerasamy, S., & Ganesan, V. K. (2022). BNP AND NT-PRO BNP AS INDEPENDENT DIAGNOSTIC BIOMARKERS FOR CARDIOVASCULAR DISEASE IN TYPE 2 DIABETES MELLITUS. Innovare Journal of Medical Sciences, 10(5), 7–8. https://doi.org/10.22159/ijms.2022.v10i5.45992

Issue

Section

Review Article(s)